The management of diabetes in Tunisia is about to experience a major evolution with the official announcement, this Saturday, May 2, 2026, of the introduction of a revolutionary new drug. This declaration follows the publication, yesterday, of the circular from the Central Pharmacy authorizing its marketing. Patients will be able to obtain this treatment in pharmacies from Wednesday May 6, 2026, according to details provided by pharmacy doctor Tayssir Ben Houria during a dedicated press conference.
A single injector pen for one month of treatment
The new device comes in the form of an injector pen containing four doses, which allows for single administration per week. Intended primarily for adults suffering from type 2 diabetes, this treatment does not just regulate blood sugar levels. Dr. Ben Houria emphasizes that its benefits extend to improving several fundamental health indicators, including reducing body weight and strengthening cardiovascular health, while ensuring safety for patients suffering from kidney failure.
Access conditions and pricing
Although the drug benefits from approval by the Ministry of Health, its use remains strictly regulated. It can only be issued upon presentation of a medical prescription from a specialist in order to ensure optimal therapeutic monitoring. The cost of a box, covering a full month of treatment, is set at 355 Tunisian dinars. In this regard, the doctor indicated that negotiations will begin soon with the National Health Insurance Fund (CNAM) in order to study the terms of coverage of this medication for those insured by social security.
Proven effectiveness and rigorous safety
The reliability of this treatment is based on large-scale clinical trials carried out on more than 10,000 patients around the world. The results demonstrate notable superiority in glycemic control and weight loss compared to traditional therapies. Already marketed in more than 70 countries, the drug was the subject of in-depth safety studies before its introduction in Tunisia. The health authorities nevertheless insist on rigorous compliance with the instructions for use and medical supervision.
The urgency faced with the scale of diabetes in Tunisia
The arrival of this therapeutic solution is part of a worrying health context, with 23% of the Tunisian population affected by diabetes. The complexity of this pathology is accentuated by a high prevalence of excess weight and obesity among patients, factors which drastically increase the risks of cardiac and renal complications. With this in mind, access to more efficient and easier-to-use treatments becomes an imperative necessity to improve the quality of life of patients.
